Last update 20 Mar 2025

Leronlimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Leronlimab (USAN/INN), Leronlimab-PRO 140, Vyrologix
+ [5]
Target
Action
antagonists
Mechanism
CCR5 antagonists(C-C chemokine receptor type 5 antagonists)
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationEmergency Use Authorization (Canada), Fast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11399Leronlimab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPhase 3
United States
01 Nov 2021
COVID-19Phase 3
United States
05 Aug 2020
HIV InfectionsPhase 2
United States
01 Nov 2021
Acute Graft Versus Host DiseasePhase 2
United States
14 May 2017
Acute Myeloid LeukemiaPhase 2
United States
14 May 2017
Myelodysplastic SyndromesPhase 2
United States
14 May 2017
HIV InfectionsDiscovery
United States
01 Nov 2021
Nonalcoholic SteatohepatitisDiscovery
United States
01 Dec 2020
Solid tumorDiscovery
United States
01 May 2020
Triple Negative Breast CancerDiscovery
United States
22 Apr 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
56
(700mg Leronlimab)
zfepvtxnep(xzcvdypmqr) = stgsdprepg voenlwkitt (vbfzhpuflc, wfauvneufg - epkqpvntxm)
-
11 Apr 2024
Placebos
(Placebo)
zfepvtxnep(xzcvdypmqr) = ikahmpedow voenlwkitt (vbfzhpuflc, pkjinufyeb - dhtwkjacsl)
Phase 2
11
Placebo
mmzygexena(hkkfcznfto) = xxgnalnkbg shrjfnkxcd (wvvqxfzlea, dbnozelqrd - uqjqvxbywg)
-
12 Mar 2024
Phase 2
43
Historical data+PRO 140
klljwyrgaa(crhbhfqywi) = xhretyjnvs ubgstpryaw (wxbsngjfuc, emtkvhkslx - epvzzbgnre)
-
14 Apr 2023
Phase 1
20
(Placebo)
sfhzudbytv(vxnhwrnkdx) = pelvxymvxi ygzfnixlad (hmqfyxcomx, qcqwnpaqmy - kukqsqgiqj)
-
14 Mar 2023
(PRO 140 Dose 1)
sfhzudbytv(vxnhwrnkdx) = fdsdvjldvg ygzfnixlad (hmqfyxcomx, ugdbntszfc - clswwatpld)
Phase 2
87
(Leronlimab 700 mg)
rvgnnoqibb(wdwvvqcann) = puujuhxkgk dtzfuupkig (lerkqswojl, vuulggrqmn - natebfdmyf)
-
01 Mar 2023
(Leronlimab 350 mg)
rvgnnoqibb(wdwvvqcann) = dqwhhddvam dtzfuupkig (lerkqswojl, nyzokmtadf - rtcpreklqh)
Phase 2
86
Placebo
(Placebo)
hfkomstfvs(beqpsqtlqa) = nhouwllbnz nxspmnjllk (yxzieuntfz, lbuujgsbzq - hrozrtbeeg)
-
04 Jan 2023
(700mg Leronlimab)
hfkomstfvs(beqpsqtlqa) = aclujtwnsc nxspmnjllk (yxzieuntfz, dacrsvkzke - oitxvtvrso)
Phase 2/3
52
Optimized Background Regimen+PRO 140
(PRO 140)
slkwlzefac(dwukyeosyd) = djhflougkr vhzhvpupnh (bqovbhutvu, lirvpvzprk - goasohjfud)
-
03 Nov 2022
Placebo
(Placebo)
slkwlzefac(dwukyeosyd) = yacjkbvkmz vhzhvpupnh (bqovbhutvu, lzobeoeeqw - wmoffyaplg)
Phase 1/2
68
(gwcrmdjtai) = lkrdknrxiu xudkzyygjn (nxfnddlzip, 2.3 - 6.2)
Positive
02 Jun 2022
Not Applicable
-
ixnrrogdke(ickbbgtjdt) = n=2 axqswetpba (wjuuhepwwm )
-
15 Feb 2022
Phase 1/2
30
Carboplatin+leronlimab
(drrhzwhpbn) = qszpaakbid speaxwizms (atmpmtuufr )
Positive
19 Jul 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free